Search clinical trials for: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

Total 320 results

Adaptimmune

Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Melanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial Carcinoma

United States, Canada, Spain
Adaptimmune

Active, not recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Melanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell Liposarcoma

United States, Canada
Adaptimmune

Completed

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Carcinoma | Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Canada
Adaptimmune

Active, not recruiting

AFPᶜ³³²T in Advanced HCC

Hepatocellular Cancer | AFP Expressing Tumors

United States, United Kingdom, France, Spain
Adaptimmune

Terminated

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

United States
In8bio Inc.

Recruiting

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Glioblastoma

United States
GlaxoSmithKline

Completed

Redirected Auto T Cells for Advanced Myeloma

Multiple Myeloma

United States
Nanfang Hospital of Southern Medical University
Guangdong Yike Gene Science and Technology CO.,Ltd

Unknown

Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified

Beta Thalassemia Major

China
University of Cologne

Unknown

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

CD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis Fungoides

Germany
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
University of Pennsylvania

Completed

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (MazF)

HIV

United States
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
Tianjin Medical University Cancer Institute and...

Unknown

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Malignant Solid Tumors

China
Adaptimmune
ICON plc

Terminated

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Esophageal Cancer | Esophagogastric Junction Cancer

United States, Canada, Spain
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 (CART-138)

Multiple Myeloma

China
Adaptimmune
GOG Foundation

Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Ovarian Cancer

United States, Spain, France, Canada, United Kingdom
T-knife GmbH

Terminated

A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (IMAG1NE)

Advanced Solid Tumors

Germany, Belgium, Spain, Netherlands, United Kingdom
Sun Yat-sen University
Guangzhou Bio-gene Technology Co., Ltd.

Unknown

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Non Small Cell Lung Cancer

China
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa Dystrophica, Recessive

United States
IRCCS San Raffaele
Orchard Therapeutics; Fondazione Telethon

Unknown

Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL)

Beta-Thalassemia

Italy
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China
Peking University
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Adaptimmune

Terminated

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Solid and Hematological Malignancies

United States, Canada
Affiliated Hospital to Academy of Military Medical...

Unknown

Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT

Acute Leukemia

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases

Non-Small-Cell Lung Cancer With Bone Metastases

China
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
University of Florida
United States Department of Defense; AM Rosen Foundation

Recruiting

Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT)

Glioblastoma | Glioblastoma Multiforme

United States
Memorial Sloan Kettering Cancer Center
Stanford University; Juno Therapeutics, Inc.

Active, not recruiting

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Solid Tumors

United States
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
Roger Williams Medical Center

Suspended

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Metastatic Cancers

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
University of Pennsylvania

Completed

Autologous Redirected RNA Meso-CIR T Cells

Malignant Pleural Mesothelioma

United States
Roger Williams Medical Center

Terminated

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Colorectal Cancer

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Beta-Thalassemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Shenzhen Geno-Immune Medical Institute

Unknown

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

Fanconi Anemia

China
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
University of Pennsylvania

Completed

Autologous CD4 T-Cells in HIV (C34-CXCR4)

Hiv

United States
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China

Search clinical trials for: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations